Is there a nebulized formulation that combines budesonide, formoterol, and glycopyrrolate similar to the Breztri dry‑powder inhaler?

No Nebulized Breztri-Equivalent Formulation Exists

There is currently no nebulized formulation that combines budesonide, formoterol, and glycopyrrolate similar to Breztri Aerosphere. Breztri is only available as a pressurized metered-dose inhaler (MDI) using co-suspension delivery technology 1.

Available Nebulized Options

While a triple-combination nebulizer solution does not exist, individual components can be nebulized separately:

Budesonide Nebulizer Solution

• Budesonide suspension for nebulization is FDA-approved and available in doses of 0.25-0.5 mg for low doses, up to 1.0-2.0 mg for higher doses 2
• This is the only inhaled corticosteroid with FDA-approved labeling for nebulization in children <4 years of age 2
• Budesonide suspension is compatible with albuterol, ipratropium, and levalbuterol in the same nebulizer chamber 2
• Must use jet nebulizers only (ultrasonic nebulizers are ineffective for suspensions) 2

Formoterol and Glycopyrrolate

• No nebulized formoterol formulation is commercially available for routine clinical use
• Ipratropium bromide (an anticholinergic like glycopyrrolate) is available for nebulization at 250-500 mcg doses 3
• Ipratropium can be combined with beta-agonists like albuterol in the same nebulizer 2

Clinical Implications

If you need triple therapy via nebulizer, you would need to:

1. Use nebulized budesonide suspension
2. Add nebulized ipratropium (as a glycopyrrolate substitute)
3. Add nebulized albuterol or levalbuterol (short-acting beta-agonists, not the long-acting formoterol)

This is NOT equivalent to Breztri because:

• You're using short-acting bronchodilators instead of long-acting ones
• Ipratropium is not identical to glycopyrrolate (though both are anticholinergics)
• Multiple separate medications increase complexity and adherence challenges

Why Nebulizers for COPD Triple Therapy?

The guidelines indicate nebulizers should only be considered when 3:

• Large drug doses are needed
• Patients cannot use hand-held inhalers effectively due to coordination difficulties
• Hand-held inhalers have been tried and proven ineffective
• Patients have chronic persistent disease at Step 4 or above

For most COPD patients requiring triple therapy, the MDI formulation of Breztri (or similar triple therapy products) remains the preferred delivery method 1, 4, 5. The co-suspension technology in Breztri MDI allows delivery of all three active ingredients in one device, improving adherence compared to multiple separate inhalers 4.